AIM:AVCT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Avacta Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVCT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.2%

AVCT

-1.8%

GB Biotechs

1.3%

GB Market


1 Year Return

359.6%

AVCT

11.5%

GB Biotechs

-15.0%

GB Market

Return vs Industry: AVCT exceeded the UK Biotechs industry which returned 11.5% over the past year.

Return vs Market: AVCT exceeded the UK Market which returned -15% over the past year.


Shareholder returns

AVCTIndustryMarket
7 Day3.2%-1.8%1.3%
30 Day-5.4%-3.4%-0.3%
90 Day539.0%24.3%18.1%
1 Year359.6%359.6%12.4%11.5%-11.0%-15.0%
3 Year50.6%50.6%8.9%7.2%-2.2%-14.2%
5 Year2.3%2.3%49.8%46.1%18.2%-8.1%

Price Volatility Vs. Market

How volatile is Avacta Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Avacta Group undervalued compared to its fair value and its price relative to the market?

8.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVCT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVCT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVCT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AVCT is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVCT is overvalued based on its PB Ratio (8.8x) compared to the GB Biotechs industry average (4.6x).


Next Steps

Future Growth

How is Avacta Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

24.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AVCT's forecast earnings growth is above the savings rate (1.2%).

Earnings vs Market: Insufficient data to determine if AVCT's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AVCT's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if AVCT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVCT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Avacta Group performed over the past 5 years?

-22.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVCT is currently unprofitable.

Growing Profit Margin: AVCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVCT is unprofitable, and losses have increased over the past 5 years at a rate of -22.5% per year.

Accelerating Growth: Unable to compare AVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: AVCT has a negative Return on Equity (-42.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Avacta Group's financial position?


Financial Position Analysis

Short Term Liabilities: AVCT's short term assets (£13.5M) exceed its short term liabilities (£2.0M).

Long Term Liabilities: AVCT's short term assets (£13.5M) exceed its long term liabilities (£646.0K).


Debt to Equity History and Analysis

Debt Level: AVCT is debt free.

Reducing Debt: AVCT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVCT has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AVCT is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Avacta Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Alastair Smith

15.5yrs

Tenure

UK£328,000

Compensation

Prof. Alastair Smith Co-founded Avacta Group Plc in January 2004 and has been its Chief Executive Officer since 2005. Prof. Smith serves as the Chief Executive Officer of Avacta Ltd. He is a Professor of M ...


CEO Compensation Analysis

Compensation vs Market: Alastair's total compensation ($USD408.93K) is below average for companies of similar size in the UK market ($USD920.57K).

Compensation vs Earnings: Alastair's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Alastair Smith
CEO & Executive Director15.5yrsUK£328.00kno data
Tony Gardiner
CFO, Company Secretary & Executive Director4.5yrsUK£245.00k0.0033% £10.7k
Matt Johnson
Chief Technology Officer4.5yrsno datano data
Amrik Basran
Chief Scientific Officer7.5yrsno datano data
Jose Saro
Chief Medical Officer1.58yrsno datano data
Michael Albin
2.33yrsUK£20.00kno data

4.5yrs

Average Tenure

Experienced Management: AVCT's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alastair Smith
CEO & Executive Director15.5yrsUK£328.00kno data
Tony Gardiner
CFO, Company Secretary & Executive Director4.5yrsUK£245.00k0.0033% £10.7k
Trevor Nicholls
Independent Non-Executive Director6.92yrsUK£46.00k0.044% £140.8k
Terence Rabbitts
Member of Scientific Advisory Board4.33yrsno datano data
Adrian Hayday
Member of Scientific Advisory Board4.33yrsno datano data
Eliot Forster
Non-Executive Chairman2.08yrsUK£120.00k0.062% £200.9k
Gerard Evan
Member of Scientific Advisory Board3.67yrsno datano data
Paul Moss
Member of Scientific Advisory Board4.33yrsno datano data
Michael Owen
Chairman of Scientific Advisory Board & Senior Independent Director4.33yrsUK£44.00kno data
Paul Fry
Non-Executive Director0.42yrno datano data

4.3yrs

Average Tenure

54yo

Average Age

Experienced Board: AVCT's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 117.5%.


Top Shareholders

Company Information

Avacta Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Avacta Group Plc
  • Ticker: AVCT
  • Exchange: AIM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£321.691m
  • Shares outstanding: 245.57m
  • Website: https://www.avacta.com

Number of Employees


Location

  • Avacta Group Plc
  • Thorp Arch Estate
  • Unit 20
  • Wetherby
  • West Yorkshire
  • LS23 7FA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVCTAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2006
AVCT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDAug 2006
RTQ1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2006

Biography

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/03 20:56
End of Day Share Price2020/07/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.